TABLE 1.

Key results of repeated European Cystic Fibrosis Society Clinical Trials Network survey to trial sites

	Week 1	Week 2	Week 4	Week 6
Dates of data collection	18–24 March	25–27 March	8–10 April	29 April to 4 May
Number of evaluable respondents	59	55	61	63
For ongoing trials, the % of clinics allowing:
Patients to attend onsite trial visits	71%	60%	57%	74.6%
New enrolment into ongoing trials	22%	15%	NA	NA
Onsite clinical research associate monitoring visits	16%	11%	NA	NA
Study drug to be shipped to patients	55%	66%	67%	65.1%
New trials
Trial set-up activities to continue	57%	60%	52%	71.4%
Site initiation visits	5%	14%	NA	NA
Initiation of CFTR modulator extension open-label studies	91%	78%	NA	NA
The % of clinics who received guidance from:
Hospital	55%	68%	NA	NA
Ethics committee	34%	23%	NA	NA
National competent authority	20%	32%	NA	NA
Sponsor	88%	90%	97%	93.7%

CFTR: cystic fibrosis transmembrane conductance regulator; NA: question not asked.